Eagle Pharma, Teva Pharma Win Patent Decision for Bendeka
28 Avril 2020 - 2:44PM
Dow Jones News
By Chris Wack
Eagle Pharmaceuticals Inc. and Teva Pharmaceutical Industries
Ltd. said Tuesday the U.S. District Court for the District of
Delaware issued a favorable patent decision for Bendeka
bendamustine hydrochloride injection, or bendamustine HCl, a
liquid, low-volume and short-time 10-minute infusion formulation of
bendamustine hydrochloride.
The companies said the court upheld the asserted patent claims
as valid and found that the defendants' proposed ANDA products
would infringe on the claims.
Under the decision, the patent defendants--Slayback Pharma LLC,
Apotex Inc. and Apotex Corp., Fresenius Kabi USA, LLC, and Mylan
Laboratories Limited--won't be able to launch their ANDA products
before 2031.
Eagle Pharmaceuticals shares rose 23% to $63.25 in premarket
trading. Teva shares rose 2% to $10.88 premarket.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 28, 2020 08:29 ET (12:29 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024